Exclusive: Third Rock's stealthy MOMA Therapeutics taps a longtime Millennium, Takeda vet as CEO
In the weeks after the Boston area first shut down for the pandemic, Asit Parikh picked up a phone and, dialing Takeda R&D chief Andy Plump, decided to end the 14-year-chapter that comprised almost the entirety of his professional career. Parikh joined Takeda in the 2008 Millennium Pharmaceuticals buyout; he led clinical studies on what would become the blockbuster Entyvio and since 2014 ran the Big Pharma’s GI division. But the pandemic had a way of making everyone take stock. “I always wanted big challenges,” he said. “It was time.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.